DSEN Research agenda

Dissemination of research results immediately upon conclusion of a research investigation back to those who originally proposed a Drug Safety and Effectiveness Network (DSEN) Query is of paramount importance and an agreed principle of DSEN-affiliated researchers. Research results remain the intellectual property of the researchers who developed the evidence.

Note: DSEN research abstracts are linked to the dates of completion in the table below as they become available.

Subject Method Completion
High potency statins and diabetes Observational studies 2014-05
Are the SNRIs duloxetine, venlafaxine and desvenlafaxine associated with renal injury (acute or chronic)? If so, is there a difference in the potential to cause renal injury among the SNRIs? Observational studies 2013-03
High-dose statins and the risk of acute kidney injury Observational studies 2012-01
Proton Pump Inhibitors (PPIs) and myocardial infarction (MI) Observational studies 2012-01
Atypical antipsychotics and breast cancer Observational studies 2012-01
Proton Pump Inhibitors (PPI) & Clostridium Difficile-Associated Diarrhea (CDAD) Observational studies 2012-01
The prevalence of atrial fibrillation related-hospitalizations Observational studies 2012-07
Safety and Effectiveness of New Oral Anti-coagulants Compared to Warfarin or Low Molecular Weight Heparin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Network meta-analysis 2012-04
Proton Pump Inhibitors and community-acquired pneumonia Observational studies 2013-07
Atypical antipsychotics and diabetic keto-acidosis (DKA_V4) (risk factors and incidence) Observational studies 2013-02
Implementation of Pharmacogenomics to Identify Patients at Risk of Statin-Induced Myopathy Pharmacogenomics of adverse drug reactions 2013-09
Validity of network meta-analyses when there is sparse evidence and utility of assessing the combined effects of drugs (e.g., drug A plus drug B vs placebo), when they have not been combined in direct RCTs. Network meta-analysis 2012-04
Network meta-analysis of cognitive enhancers for Alzheimer Dementia and mild cognitive impairment Network meta-analysis 2013-09
5-HT3 Antagonists (Antiemetics) & Cardiac Safety Network meta-analysis 2013-06
How does real world use of insulin glargine compare to NPH insulin in terms of effectiveness and safety (and ideally cost-effectiveness) for the management of type 1 diabetes mellitus? (phase 1) Network meta-analysis 2013-06
What is the real world comparative effectiveness, safety, and (ideally cost-effectiveness) of varenicline, bupropion, and nicotine replacement therapy for smoking cessation? (phase 1) Network meta-analysis 2014-12
Selective serotonin reuptake inhibitors (SSRI) and risks of fracture Network meta-analysis 2014-02
Selective serotonin reuptake inhibitors (SSRI) and risks of fracture Comparative effectiveness 2014-01
A real world distributed network study of statins and diabetes in post myocardial infarction patients Observational studies 2013-11
Identification of Pharmacogenomic Markers of Anthracycline-Induced Heart Failure in Children Pharmacogenomics of adverse drug reactions 2015-02
Date modified: